COVID-19 is an emerging, rapidly evolving situation. What people with cancer should know: https://www.cancer.gov/coronavirus. Get the latest public health information from CDC: https://www.coronavirus.gov. Get the latest research information from NIH: https://www.nih.gov/coronavirus.
This issue of CCR Milestones highlights some of our scientific advances in FY 2020-2021.
A massive DNA search brings viral dark matter into the light.
Within families of Ras/Raf proteins, individual preferences matter.
A variation of a once-banned drug proves effective for patients living with AIDS-related Kaposi sarcoma.
Learning how to design RNA-targeted therapeutics by manipulating a bacterial gene regulator.
An adjusted chemotherapy regimen provides a less toxic treatment option for adults with Burkitt lymphoma.
Long, repetitive sequences distort DNA and create a unique vulnerability in cancer cells.
A combined biopsy method leads to more accurate prostate cancer diagnoses.
Deficiencies in DNA repair may lead to higher cancer rates in African Americans diagnosed with a type of lung cancer.
Turning tumor-protecting immune cells into killer cells can strengthen the body’s fight against cancer.
A new blood test measures lifetime virus exposure to help predict risk of developing liver cancer.
A new drug shrinks tumors and improves quality of life in children.
New mouse models recreate the diversity found in human melanomas.
New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer.
We are proud of our CCR awardees who represent a spectacular array of accomplishments.
Take a look at our year as told by the numbers to see a snapshot of the breakthrough scientific discoveries and important work happening at CCR.